- NEUTRAL
Quarterly Revenue Bone Biologics Corp Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Quarterly Net Profit Bone Biologics Corp Jun-2026 Quarterly Net Profit is $-1 Million which is growth of -4.5% YoY.
0.480.00(0.00%)
26,197
XNAS Volume
XNAS 05 Oct, 2026 5:30 PM (EDT)
Bone Biologics Corp quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Bone Biologics Corp quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | ||||||||||||||
Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | |||
Gross Profit | - | - | - | - | - | - | - | - | - | |||||
| 0.8 | 0.8 | 0.7 | 0.7 | 0.8 | 1 | 1.6 | 1 | 0.8 | 0.9 | 1.2 | 2.1 | 3 | ||
Operating Profit | -0.8 | -0.8 | -0.7 | -0.7 | -0.8 | -1 | -1.6 | -1 | -0.8 | -0.9 | -1.2 | -2.1 | -3 | |
| 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | ||||||
Profit Before Tax | -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -0.9 | -0.8 | -0.9 | -1.6 | -1.9 | -1.8 | |
Tax | - | - | - | - | - | - | - | - | - | - | - | - | - | |
| -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -4.2 | -0.8 | -0.9 | -1.6 | -1.9 | -1.8 | ||
Diluted NI Avail to Com Stockholders Ann. | -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -4.2 | -0.8 | -0.9 | -1.6 | -1.9 | -1.8 | |
Basic EPS | -0.4 | -0.4 | -0.4 | -0.4 | -1.3 | -1.9 | -3.1 | -14.2 | -4 | -7.9 | -17.4 | -29.3 | -81.1 | |
Diluted EPS After ExtraOrdinary | -0.4 | -0.4 | -0.4 | -0.4 | -1.3 | -1.9 | -3.1 | -14.2 | -4.1 | -8.2 | -13 | -31.7 | -139.4 | |
Number Of Shares End | 1.8 | 1.8 | 1.8 | 1.8 | 0.6 | 0.5 | 0.5 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0 | |
Net Income Continuing Discontinued Operations | -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -0.9 | -0.8 | -0.9 | -1.6 | -1.9 | -1.8 | |
Normalized Income | -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -0.9 | -0.8 | -0.9 | -1.2 | -2.1 | -3 | |
Interest Income | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | |||||
Interest | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Net Interest Income | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | |||||
EBIT | -0.8 | -0.8 | -0.7 | -0.7 | -0.8 | -1 | -1.6 | -1 | -0.8 | -0.9 | -1.2 | -2.1 | -3 | |
EBITDA | -0.8 | -0.8 | -0.7 | -0.7 | -0.8 | -1 | -1.6 | -1 | -0.8 | -0.9 | -1.2 | -2.1 | -3 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | - | - | - | - | - | |||
Reconciled Depr. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Profit From Continuing Operations | -0.8 | -0.8 | -0.7 | -0.7 | -0.7 | -1 | -1.5 | -0.9 | -0.8 | -0.9 | -1.6 | -1.9 | -1.8 | |
Normalized EBITDA | -0.8 | -0.8 | -0.7 | -0.7 | -0.8 | -1 | -1.6 | -0.9 | -0.8 | -0.9 | -0.8 | -2.2 | -4.3 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Bone Biologics Corp competitor comparison and performance snapshot within industry
Bone Biologics Corp annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Annual Revenue Bone Biologics Corp Annual Revenue is $0 Million which is growth of 0% YoY.
- POSITIVE
Annual Net Profit Bone Biologics Corp Annual Net Profit is $-3 Million which is growth of 24.4% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | TTM | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | ||||||||||||||
Cost Of Rev. Ann. | - | - | - | - | - | ||||||||||
Gross Profit Ann. | - | - | - | - | - | ||||||||||
Operating Exp. Ann. | -4.7% | 32% | 3.1 | 3.2 | 4.2 | 9.4 | 3.7 | 1.1 | 0.8 | 2.5 | 2.8 | 2.6 | 17.9 | 12 | |
Operating Profit Ann. | - | - | -3.1 | -3.2 | -4.2 | -9.4 | -3.7 | -1.1 | -0.8 | -2.5 | -2.8 | -2.6 | -17.9 | -12 | |
- | - | 0.2 | 0.1 | 0.1 | -0.7 | -0.8 | -1 | -1 | -1.2 | -4.4 | -3.2 | -1.9 | |||
Other Exp. Ann. | -30.7% | - | 0.1 | 0.5 | 2.9 | 0.3 | - | - | -0.4 | - | - | ||||
PBT Ann. | - | - | -2.9 | -3.1 | -4.1 | -9 | -1.5 | -1.6 | -1.8 | -3.4 | -4.4 | -7.1 | -21 | -13.9 | |
Tax Ann. | - | - | - | - | - | - | 0 | ||||||||
- | - | -2.9 | -3.1 | -7.3 | -9 | -1.5 | -1.6 | -1.8 | -3.4 | -4.4 | -7.1 | -21 | -13.9 | ||
Diluted NI Avail to Com Stockholders Ann. | - | - | -2.9 | -3.1 | -7.3 | -9 | -1.5 | -1.6 | -1.8 | -3.4 | -4.4 | -7.1 | -21 | -13.9 | |
EPS Ann. | - | - | -2.7 | -29 | -204.1 | -187.2 | -504 | -900 | -1,692 | -3,168 | -6,480 | -20,160 | -15,522.3 | ||
Diluted EPS Ann. | - | - | -2.7 | -29 | -204.1 | -187.2 | -504 | -900 | -1,692 | -3,168 | -6,480 | -20,160 | -15,522.3 | ||
Number Of Shares End | - | - | 1.8 | 0.5 | 0.1 | 0 | 0 | ||||||||
Total Exp. Ann. | -4.7% | 32% | 3.2 | 4.2 | 9.4 | 3.7 | 1.1 | 0.8 | 2.5 | 2.8 | 2.6 | 17.9 | 12 | ||
Net Income Continuing Discontinued Operations Ann. | - | - | -2.9 | -3.1 | -4.1 | -9 | -1.5 | -1.6 | -1.8 | -3.4 | -4.4 | -7.1 | -21 | -13.9 | |
Normalized Income Ann. | - | - | -2.9 | -3.1 | -4.2 | -9.4 | -4.4 | -1.9 | -1.8 | -3.4 | -4 | -7.1 | -21 | -13.9 | |
Interest Income Ann. | - | - | 0.2 | 0.1 | 0.1 | - | - | - | - | - | - | - | - | ||
Interest Ann. | - | - | - | - | - | 0.8 | 1 | - | - | - | 3.2 | 1.9 | |||
EBITDA Ann. | - | - | -3.1 | -3.2 | -4.2 | -9.4 | -1.5 | -0.8 | -0.8 | -2.5 | -2.8 | -2.6 | -17.9 | -12 | |
Reconciled Cost Of Rev. Ann. | - | - | - | - | - | ||||||||||
Reconciled Depr. Ann. | - | - | - | - | - | - | - | ||||||||
Profit From Continuing Operations Ann. | - | - | -2.9 | -3.1 | -4.1 | -9 | -1.5 | -1.6 | -1.8 | -3.4 | -4.4 | -7.1 | -21 | -13.9 | |
Normalized EBITDA Ann. | - | - | -3.1 | -3.2 | -4.3 | -9.9 | -4.4 | -1.1 | -0.8 | -2.5 | -2.4 | -2.6 | -17.9 | -12 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-23.8%
2Y CAGR
-41.7%
3Y CAGR
-4.7%
5Y CAGR
32%
7Y CAGR
1.9%
10Y CAGR
-12.4%
Operating Expenses Annual Cr is falling faster than historical averages.
Bone Biologics Corp balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Total Shareholders Fund Bone Biologics Corp Dec-2025 Total Shareholders Fund is $5 Million which is growth of 54.4% YoY.
- POSITIVE
Total Assets Bone Biologics Corp Dec-2025 Total Assets is $6 Million which is growth of 50.1% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
-12% | - | 5.8 | 3.9 | 3.7 | 8.5 | 6.7 | 0 | 1 | 0.8 | 1 | 2.1 | |||
-46.4% | -50.7% | 0.4 | 0.4 | 0.8 | 2.6 | 0.1 | 13.7 | 11.9 | 9.6 | 9.2 | 9.6 | 7.8 | ||
-3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -13.7 | -11.9 | -8.6 | -8.4 | -8.6 | -5.7 | ||
Total Capitalization Ann. | -3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -13.7 | -0.6 | -8.6 | -0.2 | -2.4 | -0.1 | |
Tangible Assets Ann. | -3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -13.7 | -11.9 | -8.6 | -8.4 | -8.6 | -5.7 | |
Working Capital Ann. | -3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -13.7 | -0.6 | -8.6 | -0.2 | -2.4 | -0.1 | |
Invested Capital Ann. | -3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -2 | -0.6 | 0.4 | -0.2 | -1.2 | -0.1 | |
Tangible Book Value Ann. | -3.5% | - | 5.4 | 3.5 | 2.9 | 6 | 6.6 | -13.7 | -11.9 | -8.6 | -8.4 | -8.6 | -5.7 | |
Borrowings Ann. | - | - | - | - | - | - | - | 11.7 | 11.3 | 9 | 8.2 | 7.5 | 5.6 | |
Net Debt Ann. | - | - | - | - | - | - | - | 11.7 | 11.3 | 8 | 7.5 | 6.9 | 4.5 | |
Share Issued Ann. | - | - | 1.8 | 0.5 | 0.1 | 0 | 0 | 0 | 0 | 0 | ||||
Number Of Shares End | - | - | 1.8 | 0.5 | 0.1 | 0 | 0 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
48.7%
2Y CAGR
25.2%
3Y CAGR
-12%
7Y CAGR
28.5%
10Y CAGR
10.7%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
2Y CAGR
-29.3%
3Y CAGR
-46.4%
5Y CAGR
-50.7%
7Y CAGR
-36.5%
10Y CAGR
-15.7%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
54.3%
2Y CAGR
36.5%
3Y CAGR
-3.5%
Total ShareHolders Funds Annual growth is stable compared to historical averages.
Bone Biologics Corp ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Bone Biologics Corp Book Value Per Share is $1 which is growth of -61.2% YoY.
- NEUTRAL
ROE Bone Biologics Corp ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RoA Ann. % | - | - | - | -192.78% | -146.30% | -19.57% | -48.26% | -11,838.26% | -639.23% | -482.52% | -797.35% | -1,377.49% | -470.28% | |
ROE Ann. % | - | - | - | -229.26% | -202.15% | -23.71% | - | - | - | - | - | - | - | |
ROIC % | - | - | - | -42.4 | -46.3 | 17.3 | - | - | - | - | - | - | - | |
OPM Ann. % | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Inventory Turnover Ratio Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Asset Turnover Ann. % | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Working Capital Turnover Ann. | - | - | ||||||||||||
Quick Ratio Ann. | - | - | - | 8.8 | 3.6 | 3 | 66.8 | - | 0 | 0.1 | 0.7 | 0.2 | 0.5 | |
Current Ratio Ann. | - | - | - | 10.2 | 4.5 | 3.3 | 66.8 | - | 0.1 | 0.1 | 0.8 | 0.3 | 1 | |
Interest Coverage Ratio Ann. | - | - | - | - | - | - | -1 | -0.8 | - | - | - | -5.6 | -6.4 | |
LT Debt To Equity Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Bone Biologics Corp cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- POSITIVE
Cash From Operating Activity Bone Biologics Corp Cash From Operating Activity is $-3 Million which is growth of 34.8% YoY.
- NEUTRAL
Net Cash Flow Bone Biologics Corp Net Cash Flow is $0 Million which is growth of 0% YoY.
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | Dec '15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -2.7 | -4.1 | -9.6 | -3.6 | -1.2 | -0.4 | -3.3 | -4.1 | -3.3 | -7.3 | -3.6 | ||
- | - | - | - | - | - | - | - | - | - | - | ||||
2.2% | 63.7% | 4.7 | 4.4 | 5 | 4.4 | 7.9 | 0.4 | 2.3 | 4.4 | 3.4 | 6.8 | 2 | ||
Cash Plus Cash Eqv. End Of Year Ann. | -10.9% | - | 5.3 | 3.3 | 3 | 7.5 | 6.7 | 0 | 1 | 0.7 | 0.6 | 1.1 | ||
Net Increase In Cash Plus Cash Eqv.s Ann. | 30.5% | - | 2 | 0.3 | -4.5 | 0.9 | 6.7 | -0 | -0.9 | 0.3 | 0.1 | -0.5 | -1.6 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | -21% | - | 3.3 | 3 | 7.5 | 6.7 | 0 | 1 | 0.7 | 0.6 | 1.1 | 2.7 | ||
Income Tax Paid Supplemental Data Ann. | - | - | 0 | |||||||||||
Interest Paid Supplemental Data Ann. | - | - | - | 0 | 0.7 | 0.8 | 0.5 | 0.8 | 0.5 | |||||
Capex Ann. | - | - | - | - | - | - | - | - | - | - | - | - | ||
Issuance Of Capital Stock Ann. | 2.2% | - | 4.7 | 2.6 | 5 | 4.4 | 6.9 | - | 4.4 | 0.7 | 2.5 | - | ||
Issuance Of Debt Ann. | - | - | - | - | - | 1.1 | 0.4 | 2.3 | 0.6 | 2.7 | 3.1 | 2 | ||
Repayment Of Debt Ann. | - | - | - | - | - | -0 | - | -0.6 | - | - | - | |||
Repurchase Of Capital Stock Ann. | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Free Cash Flow Ann. | - | - | -2.7 | -4.1 | -9.6 | -3.6 | -1.2 | -0.4 | -3.3 | -4.1 | -3.3 | -7.3 | -3.6 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
6.8%
2Y CAGR
-3%
3Y CAGR
2.2%
5Y CAGR
63.7%
7Y CAGR
0.9%
10Y CAGR
8.9%
Cash from Financing Annual Activity growth is stable compared to historical averages.
